Purpose

The goal of this clinical trial is to compare ketamine to a placebo when given as a single infusion during IV sedation in adults with chronic pain and depression. We do not know whether ketamine will be more effective than placebo under these circumstances. This study aims to: - Evaluate whether ketamine is more effective than a placebo in treating chronic pain and depression - Confirm that propofol sedation is a safe way to keep participants blinded to treatment - Assess patients' comfort with the sedation process to improve future studies - Explore whether patient expectations affects their pain and depression Participants will: - Need to qualify for the study based on stringent medical criteria - Undergo sedation with propofol - Randomly receive either a ketamine or a placebo (saline) infusion during sedation - Complete several study assessments over 5-7 weeks

Conditions

Eligibility

Eligible Ages
Between 18 Years and 70 Years
Eligible Genders
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Age 18 to 70 years old - Comfortable speaking and writing in English - Chronic pain present daily for at least 3 months - Currently experiencing depression - Able to comply with the study protocol and communicate with study personnel about adverse events and other clinically important information

Exclusion Criteria

  • Pregnant or breastfeeding - One or more health conditions that makes study unsafe or unfeasible, determined by study physicians - Regular use of medications that may have problematic interactions with the study drugs - Participating in another clinical trial which may conflict with this one

Study Design

Phase
Phase 4
Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel Assignment
Primary Purpose
Treatment
Masking
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

Arm Groups

ArmDescriptionAssigned Intervention
Active Comparator
Ketamine
A one-time intravenous infusion of ketamine (0.5 mg/kg)
  • Drug: Ketamine
    0.5 mg/kg ketamine infused intravenously over 40 minutes
    Other names:
    • Ketalar
Placebo Comparator
Saline
A one-time intravenous infusion of normal saline
  • Drug: Normal saline
    0.9% normal saline infused intravenously over 40 minutes
    Other names:
    • 0.9% NaCl

Recruiting Locations

More Details

Status
Recruiting
Sponsor
Stanford University

Study Contact

Theresa Lii, MD, MS
650-264-9442
tlii@stanford.edu

Detailed Description

Ketamine is a dissociative anesthetic that has been in clinical use for more than 50 years. In addition to its well-known anesthetic and pain-relieving properties, ketamine has been found to have fast-acting antidepressant effects in patients with depression. However, the mechanisms underlying ketamine's ability to treat chronic pain and depression are poorly understood. A most basic question regarding ketamine's therapeutic mechanism is still unresolved: do patients need to consciously experience and recall ketamine's acute dissociative effects to receive lasting analgesic and antidepressant benefits? In this clinical trial, participants will receive either ketamine or a placebo when they are under sedation with propofol. A n=6 pilot feasibility phase will precede the fully-powered n=34 randomized controlled trial.

Notice

Study information shown on this site is derived from ClinicalTrials.gov (a public registry operated by the National Institutes of Health). The listing of studies provided is not certain to be all studies for which you might be eligible. Furthermore, study eligibility requirements can be difficult to understand and may change over time, so it is wise to speak with your medical care provider and individual research study teams when making decisions related to participation.